Cargando…
Updates and Recent Advances on Venom Immunotherapy
PURPOSE OF REVIEW: Venom immunotherapy has been utilized to treat Hymenoptera venom allergy since the 1920s. Over the last century, significant advances in the fields of immunology and genetics have led to improvements in the practice of venom immunotherapy. This review encompasses recent advances i...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148014/ https://www.ncbi.nlm.nih.gov/pubmed/37361640 http://dx.doi.org/10.1007/s40521-023-00336-7 |
_version_ | 1785034908780986368 |
---|---|
author | Floyd, Michelle L. Adams, Karla E. Golden, David B. K. |
author_facet | Floyd, Michelle L. Adams, Karla E. Golden, David B. K. |
author_sort | Floyd, Michelle L. |
collection | PubMed |
description | PURPOSE OF REVIEW: Venom immunotherapy has been utilized to treat Hymenoptera venom allergy since the 1920s. Over the last century, significant advances in the fields of immunology and genetics have led to improvements in the practice of venom immunotherapy. This review encompasses recent advances in the use of venom immunotherapy to provide precise, patient-centered care. RECENT FINDINGS: Research about the mechanism of action of venom immunotherapy continues to highlight the modification of both the innate and adaptive immune systems. Molecular techniques have allowed for the identification of specific venom allergens to improve the diagnostic accuracy and safety of venom immunotherapy. Research continues to support the safety of accelerated schedules which can impact the cost, adherence, and quality of life for patients receiving this treatment modality. Finally, significant advances have led to the elucidation of risk factors that place patients at risk for reactions during and after venom immunotherapy. Creation of risk profiles for venom-allergic patients can thus inform the process of immunotherapy in order to provide personalized and precise care. SUMMARY: Significant progress in the use of venom immunotherapy makes the practice a dynamic and active field for continued research. Future research needs to build on these recent advances to continue to optimize and enhance this life-saving treatment. |
format | Online Article Text |
id | pubmed-10148014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-101480142023-05-01 Updates and Recent Advances on Venom Immunotherapy Floyd, Michelle L. Adams, Karla E. Golden, David B. K. Curr Treat Options Allergy Article PURPOSE OF REVIEW: Venom immunotherapy has been utilized to treat Hymenoptera venom allergy since the 1920s. Over the last century, significant advances in the fields of immunology and genetics have led to improvements in the practice of venom immunotherapy. This review encompasses recent advances in the use of venom immunotherapy to provide precise, patient-centered care. RECENT FINDINGS: Research about the mechanism of action of venom immunotherapy continues to highlight the modification of both the innate and adaptive immune systems. Molecular techniques have allowed for the identification of specific venom allergens to improve the diagnostic accuracy and safety of venom immunotherapy. Research continues to support the safety of accelerated schedules which can impact the cost, adherence, and quality of life for patients receiving this treatment modality. Finally, significant advances have led to the elucidation of risk factors that place patients at risk for reactions during and after venom immunotherapy. Creation of risk profiles for venom-allergic patients can thus inform the process of immunotherapy in order to provide personalized and precise care. SUMMARY: Significant progress in the use of venom immunotherapy makes the practice a dynamic and active field for continued research. Future research needs to build on these recent advances to continue to optimize and enhance this life-saving treatment. Springer International Publishing 2023-04-29 /pmc/articles/PMC10148014/ /pubmed/37361640 http://dx.doi.org/10.1007/s40521-023-00336-7 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Floyd, Michelle L. Adams, Karla E. Golden, David B. K. Updates and Recent Advances on Venom Immunotherapy |
title | Updates and Recent Advances on Venom Immunotherapy |
title_full | Updates and Recent Advances on Venom Immunotherapy |
title_fullStr | Updates and Recent Advances on Venom Immunotherapy |
title_full_unstemmed | Updates and Recent Advances on Venom Immunotherapy |
title_short | Updates and Recent Advances on Venom Immunotherapy |
title_sort | updates and recent advances on venom immunotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148014/ https://www.ncbi.nlm.nih.gov/pubmed/37361640 http://dx.doi.org/10.1007/s40521-023-00336-7 |
work_keys_str_mv | AT floydmichellel updatesandrecentadvancesonvenomimmunotherapy AT adamskarlae updatesandrecentadvancesonvenomimmunotherapy AT goldendavidbk updatesandrecentadvancesonvenomimmunotherapy |